Koers Protagonist Therapeutics Inc Nasdaq
Aandelen
US74366E1029
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- PTS | - |
|
Omzet 2024 * | 292 mln. 0 272 mln. | Omzet 2025 * | 93,78 mln. 0 87,35 mln. | Marktkapitalisatie | 2,01 mld. 0 1,88 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 103 mln. - 95,94 mln. | Nettowinst (verlies) 2025 * | -34 mln. - -31,67 mln. | EV/omzet 2024 * | 4,95 x |
Nettoliquiditeiten 2024 * | 572 mln. 0 532 mln. | Nettoliquiditeiten 2025 * | 695 mln. 0 648 mln. | EV/omzet 2025 * | 14,1 x |
K/w-verhouding 2024 * |
22,6
x | K/w-verhouding 2025 * |
-25,1
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,96% |
Recentste transcriptie over Protagonist Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 67 | 01-12-08 |
Asif Ali
DFI | Director of Finance/CFO | 50 | 18-04-22 |
Chief Tech/Sci/R&D Officer | - | 01-07-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lewis Williams
BRD | Director/Board Member | 74 | 08-06-17 |
Harold Selick
CHM | Chairman | 69 | 01-02-09 |
Daniel Swisher
BRD | Director/Board Member | 61 | 26-10-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+46,03% | 55,66 mld. | |
-7,53% | 38,98 mld. | |
+36,02% | 38,8 mld. | |
-9,38% | 27,32 mld. | |
+12,31% | 26,29 mld. | |
-16,38% | 20,25 mld. | |
+30,79% | 12,76 mld. | |
+28,57% | 12,18 mld. | |
-0,36% | 12,12 mld. |
- Beurs
- Aandelen
- Koers PTGX
- Koers